S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:AXLA

Axcella Health (AXLA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.36
$0.51
50-Day Range
$0.40
$4.58
52-Week Range
$0.34
$41.25
Volume
6,700 shs
Average Volume
267,009 shs
Market Capitalization
$1.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AXLA stock logo

About Axcella Health Stock (NASDAQ:AXLA)

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

AXLA Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Axcella Health to close
Axcella Health Inc AXLA
Pre-market Movers: RLMD, BROG, VSME, AXLA, NKE…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Why Is Axcella Health (AXLA) Stock Down 24% Today?
Axcella Health stock rockets on long Covid patent win
Axcella Granted Patent for Long COVID Fatigue Treatment
Why Is Axcella Health (AXLA) Stock Up 280% Today?
Axcella Health (AXLA) Gets a Hold from H.C. Wainwright
See More Headlines
Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AXLA
Employees
11
Year Founded
N/A

Profitability

Net Income
$-81,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.42 per share

Miscellaneous

Free Float
2,883,000
Market Cap
$1.18 million
Optionable
Optionable
Beta
0.46
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Craig R. Jalbert CIRA (Age 61)
    President, CEO, Treasurer, Secretary, Financial and Accounting Officer & Director
  • Dr. Alison D. Schecter M.D. (Age 58)
    President of Strategy & Operations
    Comp: $525.53k
  • Mr. David R. Epstein B.Sc. (Age 61)
    M.B.A., Consultant
    Comp: $228.34k
  • Mr. Dan Kirby
    Senior Vice President of Strategic Operations
  • Marie Washburn
    VP of Finance & Corporate Controller
  • Dr. Karim Azer Ph.D.
    Vice President of Platform & Discovery

AXLA Stock Analysis - Frequently Asked Questions

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($10.25) earnings per share for the quarter, topping the consensus estimate of ($11.25) by $1.00.

When did Axcella Health's stock split?

Axcella Health's stock reverse split on the morning of Tuesday, September 19th 2023. The 1-25 reverse split was announced on Thursday, September 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

Axcella Health (AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Margaret Koziel, Paul Fehlner, Robert Crane and William Hinshaw.
View institutional ownership trends
.

This page (NASDAQ:AXLA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners